TIANFUCHEM--152459-95-5---Imatinib CAS NO.152459-95-5

product name:imatinibsynonyms:4-(4-methyl-piperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;imatinib (4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide;imatinib free base;veenat;imatinib(sti571);imantinib base;4-(4-methyl-piperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylam;imatinib-d4cas:152459-95-5mf:c29h31n7omw:493.6einecs:product categories:pharmaceutical intermediate;imatinib;aromatics;heterocycles;impurities;intermediates & fine chemicals;pharmaceuticals;api;gleveec;antineoplastic;anti-cancer & immunity;inhibitors;molecular targeted antineoplasticmol file:152459-95-5.mol

imatinib chemical properties
melting point 208-210°c (dec.)storage temp. refrigeratorpkapka1 8.07; pka2 3.73; pka3 2.56; pka4 1.52(at 25℃)merck 14,4902cas database reference152459-95-5(cas database reference)
safety information
safety statements 24/25rtecs cv5585673
msds information
imatinib usage and synthesis
product descriptionimatinib is a kind of oral drugs used for the treatment of the chronic myelogenous leukemia (abbreviated cml) of positive symptoms of philadelphia chromosome (ber-abl). it is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon. cml is a kind of hematopoietic stem cell disease caused by the dna abnormalities in the bone marrow stem cells. dna abnormalities will produce abnormal proteins and interfere with the normal generation process of the white blood cells in the bone marrow, resulting in the sharp increase in the number of white blood cells. cml is divided into three phases including chronic phase, accelerated phase and crisis phase with the average survival period of the patients in crisis phase being only 2-3 months.
imatinib is also effective in treating the gastrointestinal stromal tumor with the efficiency being about 50%.approved indications in europe, the united states and other countriesnovartis's imatinib (imatinib, glivec) had been approved in switzerland for being used as first-line drug for the treatment of early-stage adult chronic myelogenous leukemia and can also be applied to patients with various types of chronic granulocytic leukemia. switzerland is the first countries which had approved to additionally include the above two indications of this drug.
on july 28, 2006, the european agency for the evaluation of medicinal products (emea) had recommended the imatinib (gleevec) of the novartis company for the treatment of two new indications-dermatofibrosarcoma protuberans (dfsp) and philadelphia chromosome-positive acute lymphoblastic leukemia (ph + all). these final approvals of these two indications still need to wait the decision of the european food and drug administration.
in addition, novartis has announced that the application of imatinib in treating hypereosinophilic syndrome and systemic mastocytosis is still in the approval process of fda and emea.
the drug has currently been approved in europe, the united states and other countries for the treatment of philadelphia chromosome-positive chronic myeloid leukemia (ph + cml) and gastrointestinal stromal tumors.
the above information is edited by the chemicalbook of dai xiongfeng.precautionswhen combined with ketoconazole, itraconazole, erythromycin, clarithromycin, the cmax of this drug can (the maximum plasma concentration after the first drug administration) be increased by an average of 26% with the auc being increased by 40%.
the inducers of the metabolizing enzyme of hepatic drugs such as dexamethasone, phenytoin, carbamazepine, rifampicin and barbiturates can significantly reduce blood concentration of the drug.
when the cyp3a4 metabolized substrates such as simvastatin, cyclosporine, pimozide, etc. were used in combined with imatinib, the plasma concentration of those drugs can be increased due to its competing with the drug enzyme.usesimatinib can be used for the treatment of the chronic myelogenous leukemia (abbreviated cml) of positive symptoms of philadelphia chromosome (ber-abl). it is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon.chemical propertiesorange solidusesimatinib mesylate is orally bioavailability mesylate salt of imatinib, which is a multi-target inhibitor of v-abl, c-kit and pdgfr with ic50 of 0.6 μm, 0.1 μm and 0.1 μm, respectively. imatinib also known as gleevec, glivec, cgp-57148b, sti-571 & imatinibusesantineoplasticusesatypical antipsychoticusesimatinib impurity.